WALTHAM, Mass.

马萨诸塞州沃尔瑟姆

,

，

Nov. 10, 2026

2026年11月10日

/PRNewswire/ -- EnVision Endoscopy, Inc., a medical technology company developing innovative solutions for gastrointestinal (GI) endoscopic surgery, today announced the successful closing of an oversubscribed $11.5 million Series A financing and the completion of its first 50 patient procedures using the SimpleStitch™ Suturing System..

/美通社/ -- 专注于开发胃肠道（GI）内镜手术创新解决方案的医疗科技公司EnVision Endoscopy, Inc.今日宣布，成功完成超额认购的1150万美元A轮融资，并使用其SimpleStitch™缝合系统完成了首批50例患者手术。

Together, these milestones mark a significant step in the company's transition from technology development to clinical adoption and commercial expansion, supporting its mission to make endoscopic suturing more accessible to physicians performing minimally invasive gastrointestinal procedures.

这些里程碑共同标志着该公司从技术开发向临床应用和商业扩展转型的重要一步，有助于实现其使命，使进行微创胃肠手术的医生能够更便捷地使用内镜缝合技术。

Designed for use with standard flexible endoscopes, the SimpleStitch™ Suturing System is intended to help physicians with an intuitive approach and easy-to-use technology to perform endoscopic suturing. The technology is designed to address longstanding challenges associated with tissue closure following advanced gastrointestinal endoscopic procedures, potentially expanding access to suturing beyond specialized expert centers..

SimpleStitch™缝合系统专为配合标准柔性内窥镜使用而设计，旨在通过直观的方法和易于操作的技术，帮助医师完成内镜下缝合。该技术旨在解决高级胃肠道内镜手术后组织闭合长期面临的挑战，有望将缝合技术的应用范围从专业专家中心扩展至更广泛的医疗机构。

EnVision received FDA clearance for the SimpleStitch™ Suturing System in 2025 and initiated a limited U.S. market release in 2026. The completion of the first 50 patient procedures represents an important milestone in building clinical experience, strengthening physician partnerships, and advancing the company's commercial strategy..

EnVision于2025年获得美国食品药品监督管理局（FDA）对SimpleStitch™缝合系统的批准，并于2026年启动了在美国市场的有限发布。完成首批50例患者手术标志着在积累临床经验、加强医师合作关系以及推进公司商业化战略方面的重要里程碑。

'Technologies to simplify endoscopic resection are coming, and closure should be even simpler. SimpleStitch™ bridges the gap between conventional clips and advanced endoscopic suturing, making strong, confident tissue closure more accessible. I'm excited that 50 procedures have now been safely completed at pilot sites in 2026.

简化内镜切除的技术正在涌现，而闭合操作应更加简便。SimpleStitch™ 弥合了传统夹子与先进内镜缝合技术之间的差距，使强韧、可靠的组织闭合更易实现。令人振奋的是，截至2026年，试点中心已安全完成50例手术。

This is an important step toward bringing better closure options to physicians and their patients,' said Dr. Andrew Storm of Atrium Health Wake Forest Baptist, who performed the first-in-human procedure with SimpleStitch™..

“这是为医生及其患者提供更优闭合方案的重要一步，”Atrium Health Wake Forest Baptist 的安德鲁·斯托姆博士表示，他使用 SimpleStitch™ 完成了全球首例人体手术。

'We founded EnVision to address persistent challenges in endoscopic surgery. Reaching our first 50 patient procedures validates the work of our team and physician collaborators in bringing SimpleStitch™ into clinical practice. Combined with our Series A financing, this milestone positions us to build on that momentum and bring our technology to more physicians and patients,' said Azadeh Khanicheh, Ph.D., Co-Founder and Chief Executive Officer of EnVision Endoscopy..

“我们创立EnVision旨在解决内窥镜手术中长期存在的挑战。完成首批50例患者手术，验证了我们团队与医师合作者在将SimpleStitch™引入临床实践方面的工作成果。结合我们的A轮融资，这一里程碑使我们能够在此基础上继续推进，将我们的技术带给更多的医师和患者。”EnVision Endoscopy联合创始人兼首席执行官Azadeh Khanicheh博士表示。

Series A Financing to Support Commercial Expansion

A轮融资以支持商业化扩张

The oversubscribed $11.5 million Series A financing was led by Puma Venture Capital, with participation from UTEC – University of Tokyo Edge Capital, existing investor Olympus Corporation of the Americas, and MassVentures.

这轮超额认购的1150万美元A轮融资由Puma风险投资公司领投，东京大学边缘资本（UTEC）、现有投资者奥林巴斯美洲公司以及MassVentures参与投资。

'Puma backs minimally invasive technologies that can improve both labor productivity and how well patients do. SimpleStitch™ takes endoscopic suturing out of a handful of expert centers and puts it on the scope a physician already owns. More endoscopists can close with confidence, more patients get a less invasive option, and that's why we led this round,' said Amit Hazan, Co-Founder and Managing Partner of Puma Venture Capital..

“Puma 支持能够同时提升劳动生产率和患者预后的微创技术。SimpleStitch™ 让内镜缝合技术不再局限于少数专家中心，而是直接应用于医生已有的内镜设备上。更多内镜医师可以自信地完成闭合操作，更多患者能够获得创伤更小的治疗选择，这也是我们领投本轮融资的原因。”Puma 风险投资的联合创始人兼管理合伙人 Amit Hazan 表示。

The financing will support EnVision Endoscopy's next phase of growth, including expanded commercial availability, physician training, clinical evidence generation, manufacturing scale-up, and further product development.

这笔融资将支持 EnVision Endoscopy 的下一阶段增长，包括扩大商业化供应、医师培训、生成临床证据、扩大制造规模以及进一步的产品开发。

The strong investor participation reflects confidence in EnVision Endoscopy's technology, its approach to addressing unmet needs in gastrointestinal endoscopic surgery, and the growing opportunity to advance minimally invasive endoscopic interventions.

投资者的踊跃参与反映出市场对EnVision Endoscopy技术的信心，对其满足胃肠道内镜手术未竟需求之方法的认可，以及对推进微创内镜干预措施日益增长的市场机遇的看好。

Addressing a Growing Need for Endoscopic Closure

应对内镜闭合日益增长的需求

Endoscopy is steadily replacing surgery for a growing range of gastrointestinal conditions. More than 20 million gastrointestinal endoscopic procedures are performed in the U.S. each year, and advanced resection techniques such as endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), and peroral endoscopic myotomy (POEM) are being adopted rapidly in the U.S.

内镜检查正稳步取代手术，用于越来越多类型的胃肠道疾病。美国每年进行的胃肠道内镜操作超过2000万例，而诸如内镜黏膜切除术（EMR）、内镜黏膜下剥离术（ESD）和经口内镜肌切开术（POEM）等高级切除技术在美国正被迅速采纳。

and Europe. Each of these procedures can leave defects that need secure closure..

以及欧洲。这些操作中的每一种都可能留下需要严密闭合的缺陷。

The endoscopic closure device market is projected to grow 7–8% annually through the end of the decade. Yet endoscopic suturing remains concentrated in a small number of expert centers, because existing systems require extensive training and dedicated equipment. SimpleStitch™ is designed to close this gap by bringing suturing to the broader community of endoscopists using the endoscopes they already have..

预计到本十年末，内镜闭合装置市场将以每年7%至8%的速度增长。然而，由于现有系统需要大量的培训和专用设备，内镜缝合技术仍集中在少数专家中心。SimpleStitch™旨在通过让更广泛的内镜医师群体能够使用他们现有的内镜进行缝合，从而缩小这一差距。

About EnVision Endoscopy, Inc.

关于 EnVision Endoscopy, Inc.

EnVision Endoscopy, Inc. is a Waltham, Massachusetts-based medical technology company developing innovative devices for gastrointestinal endoscopic surgery. Co-founded by Azadeh Khanicheh, Ph.D., and Christopher C. Thompson, MD, MSc, the company is focused on addressing unmet clinical needs through technologies that support less invasive endoscopic procedures..

EnVision Endoscopy, Inc. 是一家总部位于马萨诸塞州沃尔瑟姆的医疗技术公司，致力于开发用于胃肠道内镜手术的创新器械。该公司由 Azadeh Khanicheh 博士和 Christopher C. Thompson 医学博士、理学硕士联合创立，专注于通过支持微创内镜手术的技术来满足尚未被满足的临床需求。

Its SimpleStitch™ Suturing System is designed to facilitate endoscopic suturing and tissue approximation using standard flexible endoscopes. EnVision's mission is to advance endoscopic surgery through practical, innovative technologies that serve physicians and patients.

其SimpleStitch™缝合系统旨在利用标准柔性内窥镜促进内镜下缝合及组织对合。EnVision的使命是通过服务于医师和患者的实用创新技术，推动内镜手术的发展。

For more information, visit:

更多信息，请访问：

www.envisionendoscopy.com

www.envisionendoscopy.com

SOURCE ENVISION ENDOSCOPY INC.

来源：ENVISION 内窥镜公司